CMV Immune Response & Long-Term Outcome of CMV Retinitis
CMV Immune Response & Long-Term Outcome of CMV Retinitis
批准号:
6848025
负责人:
MARK A JACOBSON
金额:
$25.92万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-02-01 至 2007-01-31
关键词:
AIDS therapycytomegaloviruscytomegalovirus retinitiscytotoxic T lymphocyteflow cytometryhelper T lymphocytehuman tissueimmune responseimmunologic assay /testinterferon gammaleukocyte activation /transformationmicroorganism disease chemotherapyoutcomes researchpolymerase chain reactionprognosisvirus load
中文摘要
描述(由申请人提供):这项建议的目的是测试CMV特异性免疫分析的潜在临床效用,该方法与保护性CMV特异性免疫反应相关,并可以告知临床医生何时开始、停止或重新实施抗CMV治疗是最佳的,以防止有这种机会性感染风险或已经被诊断为CMV视网膜炎(CMVR)的艾滋病患者发生和进行性CMV视网膜炎,从而防止他们未来的视力丧失。这项拟议的工作将调查这样一种假设,即CD8+T淋巴细胞IFNG反应(用CMV pp65和IE蛋白的短、重叠多肽以及整个CMV裂解物刺激后用流式细胞仪测量)将准确预测临床CMVR结果。具体地说,主要目的是比较国家眼科研究所赞助的艾滋病眼部并发症多中心纵向研究(LSOCA)中储存的PBMC样本中CMV刺激的CD8+/IFNG+T淋巴细胞反应,这些样本来自CMVR事件或进展事件之前的病例组,以及研究中没有后续事件或进展事件的匹配对照组LSOCA受试者。主要的次要目标是确定其他临床特征(使用HAART、使用抗CMV治疗)、标准临床实验室测量(血浆HIV RNA、血红蛋白)或测量CMV病毒血症(通过血浆CMV DNA)是否会增强测量CMV抗原特异性CD8+/IFNG+T淋巴细胞反应对发生或进展CMVR的预测价值。这项拟议的工作将采用观察性病例对照研究设计。研究人群将由已经在LSOCA注册并且目前有中位数2年随访的受试者组成。作为LSOCA方案的一部分,收集了大量的临床数据,并将其输入由约翰霍普金斯大学公共卫生学院SOCA协调中心管理的中央数据库。PMBC样本是在LSOCA授权的所有研究访问中获得的,并存储在中央存储库中。拟议的工作包括对已经获得并作为LSOCA协议一部分存储的PBMC样本进行CMV抗原特异性免疫分析测试,然后分析免疫分析结果与作为LSOCA协议一部分收集的其他临床数据的关系,包括通过对视网膜照片进行中央掩蔽分析确认的CMVR结果。
英文摘要
DESCRIPTION (provided by applicant): The aim of this proposal is to test the potential clinical utility of a CMV-specific immunoassay that correlates with protective CMV-specific immune responses and which could inform clinicians when it is optimal to initiate, discontinue or re-institute anti-CMV therapy in order to prevent incident and progressive CMV retinitis (CMVR) in AIDS patients at risk for or already diagnosed with this opportunistic infection and thus prevent their future vision loss. The proposed work will investigate the hypothesis that CD8+ T lymphocyte IFNg responses (measured by flow cytometry after stimulation with short, overlapping peptides of the CMV pp65 and IE proteins, as well as with whole CMV lysate) will accurately predict clinical CMVR outcomes. Specifically, the primary objective is to compare CMV-stimulated CD8+/IFNg+ T lymphocyte responses by flow cytometry in stored PBMC samples obtained in the National Eye Institute-sponsored multi-center Longitudinal Study of the Ocular Complications of AIDS (LSOCA) from groups of cases prior to CMVR incident or progression events and from groups of matched control LSOCA subjects who had no subsequent incident or progressive CMVR event on study. The main secondary objective is to determine if additional clinical characteristics (use of HAART, use of anti-CMV therapy), standard clinical laboratory measurements (plasma HIV RNA, hemoglobin) or measurement of CMV viremia (by plasma CMV DNA) will enhance the predictive value of measuring CMV antigen-specific CD8+/IFNg+ T lymphocyte responses for incident or progressive CMVR. The proposed work will employ an observational, case-control study design. The study population will consist of subjects who have already been enrolled in LSOCA and currently have a median 2 years of follow-up. Extensive clinical data are collected as part of the LSOCA protocol and entered into a central database managed at the SOCA Coordinating Center at Johns Hopkins School of Public Health. PMBC specimens are obtained at all LSOCA-mandated study visits and banked in a central repository. The proposed work involves CMV-antigen specific immunoassay testing of stored PBMC specimens that have already been obtained and stored as part of the LSOCA protocol and then analyzing the relationship of the immunoassay results to other clinical data already collected as part of the LSOCA protocol, including CMVR outcomes that are confirmed by central masked analysis of retinal photographs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV Epitope Specific T Cell Responses and Control of HIV Replication
-
批准号:7282098
-
项目类别:
-
资助金额:$23.09万
-
财政年份:2007
-
负责人:MARK A JACOBSON
-
依托单位:
Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
-
批准号:7336264
-
项目类别:
-
资助金额:$23.11万
-
财政年份:2007
-
负责人:MARK A JACOBSON
-
依托单位:
HIV Epitope Specific T Cell Responses and Control of HIV Replication
-
批准号:7417845
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2007
-
负责人:MARK A JACOBSON
-
依托单位:
Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
-
批准号:7489883
-
项目类别:
-
资助金额:$18.93万
-
财政年份:2007
-
负责人:MARK A JACOBSON
-
依托单位:
CMV Immune Response & Long-Term Outcome of CMV Retinitis
-
批准号:6745723
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
THE ROLE OF PROTEIN LOOP FLEXIBILITY IN SUBSTRATE BINDING
-
批准号:7181783
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
AACTG 5079: PHYSIOLOGIC TESTOSTERONE
-
批准号:7203030
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
ADJUVANT RHIL-12 WITH A CYTOMEGALOVIRUS
-
批准号:7203039
-
项目类别:
-
资助金额:$30.09万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
AACTG 5079: Physiologic testosterone
-
批准号:7044942
-
项目类别:
-
资助金额:$0.57万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
A5159: HIV protease inhibitors and calcium channel blockers
-
批准号:7044955
-
项目类别:
-
资助金额:$0.57万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
ADJUVANT RHIL-12 WITH A CYTOMEGALOVIRUS
-
批准号:7044951
-
项目类别:
-
资助金额:$4.95万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
ACTG 5077: HAART/HIV compartments
-
批准号:7044920
-
项目类别:
-
资助金额:$0.98万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
AACTG A5082: Metformin/ Rosiglitazone
-
批准号:7044930
-
项目类别:
-
资助金额:$0.9万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
Adjunct rhIL-12 enhance THI response to viral vaccine?
-
批准号:6467926
-
项目类别:
-
资助金额:$50.48万
-
财政年份:2002
-
负责人:MARK A JACOBSON
-
依托单位:
Adjunct rhIL-12 enhance THI response to viral vaccine?
-
批准号:6623575
-
项目类别:
-
资助金额:$29.1万
-
财政年份:2002
-
负责人:MARK A JACOBSON
-
依托单位:
Adjunct rhIL-12 enhance THI response to viral vaccine?
-
批准号:6737543
-
项目类别:
-
资助金额:$10.37万
-
财政年份:2002
-
负责人:MARK A JACOBSON
-
依托单位:
CORE--CLINICAL
-
批准号:6453039
-
项目类别:
-
资助金额:$13.19万
-
财政年份:2001
-
负责人:MARK A JACOBSON
-
依托单位:
CORE--CLINICAL
-
批准号:6507450
-
项目类别:
-
资助金额:$16.54万
-
财政年份:2001
-
负责人:MARK A JACOBSON
-
依托单位:
CORE--CLINICAL
-
批准号:6302657
-
项目类别:
-
资助金额:$34.93万
-
财政年份:2000
-
负责人:MARK A JACOBSON
-
依托单位:
CORE--ADVANCED TECHNOLOGY LABORATORIES
-
批准号:6099319
-
项目类别:
-
资助金额:$15.75万
-
财政年份:1999
-
负责人:MARK A JACOBSON
-
依托单位:
海外基金